Deucravacitinib for Psoriasis

This article reviews the mechanism and significance of TYK2 inhibition, as well as the current data on the safety and efficacy of deucravacitinib.Recent FindingsPhase II results for deucravacitinib have shown that four out of six treatment groups resulted in statistically significant increases in PASI75 improvement over the placebo group. The most common adverse effects were headache, nasopharyngitis, upper respiratory tract infection, nausea, acne, and diarrhea. Three serious adverse events were noted in the treatment group, and they were gastroenteritis due to rotavirus, accidental eye injury, and dizziness.SummaryDeucravacitinib holds great promise to meet the unfulfilled need for an efficacious oral small molecule treatment for psoriasis. However, phase III results will be needed to confirm the safety profile seen in phase I and phase II trials.
Source: Current Dermatology Reports - Category: Dermatology Source Type: research